Index
1 Market Overview
1.1 Product Overview and Scope of Peptide and Oligonucleotide CDMO
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Peptide and Oligonucleotide CDMO by Type
1.3.1 Overview: Global Peptide and Oligonucleotide CDMO Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Peptide and Oligonucleotide CDMO Consumption Value Market Share by Type in 2022
1.3.3 Peptide CDMO
1.3.4 Oligonucleotide CDMO
1.4 Global Peptide and Oligonucleotide CDMO Market by Application
1.4.1 Overview: Global Peptide and Oligonucleotide CDMO Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Pharmaceutical and Biotechnology Companies
1.4.3 Research Institutes
1.4.4 Others
1.5 Global Peptide and Oligonucleotide CDMO Market Size & Forecast
1.6 Global Peptide and Oligonucleotide CDMO Market Size and Forecast by Region
1.6.1 Global Peptide and Oligonucleotide CDMO Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Peptide and Oligonucleotide CDMO Market Size by Region, (2018-2029)
1.6.3 North America Peptide and Oligonucleotide CDMO Market Size and Prospect (2018-2029)
1.6.4 Europe Peptide and Oligonucleotide CDMO Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Peptide and Oligonucleotide CDMO Market Size and Prospect (2018-2029)
1.6.6 South America Peptide and Oligonucleotide CDMO Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Peptide and Oligonucleotide CDMO Market Size and Prospect (2018-2029)
2 Company Profiles
2.1 Lonza Group Ltd.
2.1.1 Lonza Group Ltd. Details
2.1.2 Lonza Group Ltd. Major Business
2.1.3 Lonza Group Ltd. Peptide and Oligonucleotide CDMO Product and Solutions
2.1.4 Lonza Group Ltd. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Lonza Group Ltd. Recent Developments and Future Plans
2.2 Thermo Fisher Scientific Inc.
2.2.1 Thermo Fisher Scientific Inc. Details
2.2.2 Thermo Fisher Scientific Inc. Major Business
2.2.3 Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO Product and Solutions
2.2.4 Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Thermo Fisher Scientific Inc. Recent Developments and Future Plans
2.3 Merck KGaA
2.3.1 Merck KGaA Details
2.3.2 Merck KGaA Major Business
2.3.3 Merck KGaA Peptide and Oligonucleotide CDMO Product and Solutions
2.3.4 Merck KGaA Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Merck KGaA Recent Developments and Future Plans
2.4 Catalent, Inc.
2.4.1 Catalent, Inc. Details
2.4.2 Catalent, Inc. Major Business
2.4.3 Catalent, Inc. Peptide and Oligonucleotide CDMO Product and Solutions
2.4.4 Catalent, Inc. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Catalent, Inc. Recent Developments and Future Plans
2.5 Genscript Biotech Corporation
2.5.1 Genscript Biotech Corporation Details
2.5.2 Genscript Biotech Corporation Major Business
2.5.3 Genscript Biotech Corporation Peptide and Oligonucleotide CDMO Product and Solutions
2.5.4 Genscript Biotech Corporation Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Genscript Biotech Corporation Recent Developments and Future Plans
2.6 Polypeptide Group
2.6.1 Polypeptide Group Details
2.6.2 Polypeptide Group Major Business
2.6.3 Polypeptide Group Peptide and Oligonucleotide CDMO Product and Solutions
2.6.4 Polypeptide Group Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Polypeptide Group Recent Developments and Future Plans
2.7 Bachem Holding AG
2.7.1 Bachem Holding AG Details
2.7.2 Bachem Holding AG Major Business
2.7.3 Bachem Holding AG Peptide and Oligonucleotide CDMO Product and Solutions
2.7.4 Bachem Holding AG Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Bachem Holding AG Recent Developments and Future Plans
2.8 Wuxi Apptec Co., Ltd.
2.8.1 Wuxi Apptec Co., Ltd. Details
2.8.2 Wuxi Apptec Co., Ltd. Major Business
2.8.3 Wuxi Apptec Co., Ltd. Peptide and Oligonucleotide CDMO Product and Solutions
2.8.4 Wuxi Apptec Co., Ltd. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Wuxi Apptec Co., Ltd. Recent Developments and Future Plans
2.9 Ajinomoto Co., Inc.
2.9.1 Ajinomoto Co., Inc. Details
2.9.2 Ajinomoto Co., Inc. Major Business
2.9.3 Ajinomoto Co., Inc. Peptide and Oligonucleotide CDMO Product and Solutions
2.9.4 Ajinomoto Co., Inc. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Ajinomoto Co., Inc. Recent Developments and Future Plans
2.10 Rentschler Biopharma SE
2.10.1 Rentschler Biopharma SE Details
2.10.2 Rentschler Biopharma SE Major Business
2.10.3 Rentschler Biopharma SE Peptide and Oligonucleotide CDMO Product and Solutions
2.10.4 Rentschler Biopharma SE Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Rentschler Biopharma SE Recent Developments and Future Plans
2.11 Corden Pharma GmbH
2.11.1 Corden Pharma GmbH Details
2.11.2 Corden Pharma GmbH Major Business
2.11.3 Corden Pharma GmbH Peptide and Oligonucleotide CDMO Product and Solutions
2.11.4 Corden Pharma GmbH Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Corden Pharma GmbH Recent Developments and Future Plans
2.12 Senn Chemicals AG
2.12.1 Senn Chemicals AG Details
2.12.2 Senn Chemicals AG Major Business
2.12.3 Senn Chemicals AG Peptide and Oligonucleotide CDMO Product and Solutions
2.12.4 Senn Chemicals AG Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Senn Chemicals AG Recent Developments and Future Plans
2.13 Almac Group
2.13.1 Almac Group Details
2.13.2 Almac Group Major Business
2.13.3 Almac Group Peptide and Oligonucleotide CDMO Product and Solutions
2.13.4 Almac Group Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 Almac Group Recent Developments and Future Plans
2.14 Lonza Custom Manufacturing
2.14.1 Lonza Custom Manufacturing Details
2.14.2 Lonza Custom Manufacturing Major Business
2.14.3 Lonza Custom Manufacturing Peptide and Oligonucleotide CDMO Product and Solutions
2.14.4 Lonza Custom Manufacturing Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 Lonza Custom Manufacturing Recent Developments and Future Plans
2.15 Creative Peptides
2.15.1 Creative Peptides Details
2.15.2 Creative Peptides Major Business
2.15.3 Creative Peptides Peptide and Oligonucleotide CDMO Product and Solutions
2.15.4 Creative Peptides Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.15.5 Creative Peptides Recent Developments and Future Plans
2.16 Swiss Customized Synthesis
2.16.1 Swiss Customized Synthesis Details
2.16.2 Swiss Customized Synthesis Major Business
2.16.3 Swiss Customized Synthesis Peptide and Oligonucleotide CDMO Product and Solutions
2.16.4 Swiss Customized Synthesis Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.16.5 Swiss Customized Synthesis Recent Developments and Future Plans
2.17 Syngene
2.17.1 Syngene Details
2.17.2 Syngene Major Business
2.17.3 Syngene Peptide and Oligonucleotide CDMO Product and Solutions
2.17.4 Syngene Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.17.5 Syngene Recent Developments and Future Plans
2.18 Eurogentec
2.18.1 Eurogentec Details
2.18.2 Eurogentec Major Business
2.18.3 Eurogentec Peptide and Oligonucleotide CDMO Product and Solutions
2.18.4 Eurogentec Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.18.5 Eurogentec Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Peptide and Oligonucleotide CDMO Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Peptide and Oligonucleotide CDMO by Company Revenue
3.2.2 Top 3 Peptide and Oligonucleotide CDMO Players Market Share in 2022
3.2.3 Top 6 Peptide and Oligonucleotide CDMO Players Market Share in 2022
3.3 Peptide and Oligonucleotide CDMO Market: Overall Company Footprint Analysis
3.3.1 Peptide and Oligonucleotide CDMO Market: Region Footprint
3.3.2 Peptide and Oligonucleotide CDMO Market: Company Product Type Footprint
3.3.3 Peptide and Oligonucleotide CDMO Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
4.1 Global Peptide and Oligonucleotide CDMO Consumption Value and Market Share by Type (2018-2023)
4.2 Global Peptide and Oligonucleotide CDMO Market Forecast by Type (2024-2029)
5 Market Size Segment by Application
5.1 Global Peptide and Oligonucleotide CDMO Consumption Value Market Share by Application (2018-2023)
5.2 Global Peptide and Oligonucleotide CDMO Market Forecast by Application (2024-2029)
6 North America
6.1 North America Peptide and Oligonucleotide CDMO Consumption Value by Type (2018-2029)
6.2 North America Peptide and Oligonucleotide CDMO Consumption Value by Application (2018-2029)
6.3 North America Peptide and Oligonucleotide CDMO Market Size by Country
6.3.1 North America Peptide and Oligonucleotide CDMO Consumption Value by Country (2018-2029)
6.3.2 United States Peptide and Oligonucleotide CDMO Market Size and Forecast (2018-2029)
6.3.3 Canada Peptide and Oligonucleotide CDMO Market Size and Forecast (2018-2029)
6.3.4 Mexico Peptide and Oligonucleotide CDMO Market Size and Forecast (2018-2029)
7 Europe
7.1 Europe Peptide and Oligonucleotide CDMO Consumption Value by Type (2018-2029)
7.2 Europe Peptide and Oligonucleotide CDMO Consumption Value by Application (2018-2029)
7.3 Europe Peptide and Oligonucleotide CDMO Market Size by Country
7.3.1 Europe Peptide and Oligonucleotide CDMO Consumption Value by Country (2018-2029)
7.3.2 Germany Peptide and Oligonucleotide CDMO Market Size and Forecast (2018-2029)
7.3.3 France Peptide and Oligonucleotide CDMO Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Peptide and Oligonucleotide CDMO Market Size and Forecast (2018-2029)
7.3.5 Russia Peptide and Oligonucleotide CDMO Market Size and Forecast (2018-2029)
7.3.6 Italy Peptide and Oligonucleotide CDMO Market Size and Forecast (2018-2029)
8 Asia-Pacific
8.1 Asia-Pacific Peptide and Oligonucleotide CDMO Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Peptide and Oligonucleotide CDMO Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Peptide and Oligonucleotide CDMO Market Size by Region
8.3.1 Asia-Pacific Peptide and Oligonucleotide CDMO Consumption Value by Region (2018-2029)
8.3.2 China Peptide and Oligonucleotide CDMO Market Size and Forecast (2018-2029)
8.3.3 Japan Peptide and Oligonucleotide CDMO Market Size and Forecast (2018-2029)
8.3.4 South Korea Peptide and Oligonucleotide CDMO Market Size and Forecast (2018-2029)
8.3.5 India Peptide and Oligonucleotide CDMO Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Peptide and Oligonucleotide CDMO Market Size and Forecast (2018-2029)
8.3.7 Australia Peptide and Oligonucleotide CDMO Market Size and Forecast (2018-2029)
9 South America
9.1 South America Peptide and Oligonucleotide CDMO Consumption Value by Type (2018-2029)
9.2 South America Peptide and Oligonucleotide CDMO Consumption Value by Application (2018-2029)
9.3 South America Peptide and Oligonucleotide CDMO Market Size by Country
9.3.1 South America Peptide and Oligonucleotide CDMO Consumption Value by Country (2018-2029)
9.3.2 Brazil Peptide and Oligonucleotide CDMO Market Size and Forecast (2018-2029)
9.3.3 Argentina Peptide and Oligonucleotide CDMO Market Size and Forecast (2018-2029)
10 Middle East & Africa
10.1 Middle East & Africa Peptide and Oligonucleotide CDMO Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Peptide and Oligonucleotide CDMO Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Peptide and Oligonucleotide CDMO Market Size by Country
10.3.1 Middle East & Africa Peptide and Oligonucleotide CDMO Consumption Value by Country (2018-2029)
10.3.2 Turkey Peptide and Oligonucleotide CDMO Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Peptide and Oligonucleotide CDMO Market Size and Forecast (2018-2029)
10.3.4 UAE Peptide and Oligonucleotide CDMO Market Size and Forecast (2018-2029)
11 Market Dynamics
11.1 Peptide and Oligonucleotide CDMO Market Drivers
11.2 Peptide and Oligonucleotide CDMO Market Restraints
11.3 Peptide and Oligonucleotide CDMO Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War
12 Industry Chain Analysis
12.1 Peptide and Oligonucleotide CDMO Industry Chain
12.2 Peptide and Oligonucleotide CDMO Upstream Analysis
12.3 Peptide and Oligonucleotide CDMO Midstream Analysis
12.4 Peptide and Oligonucleotide CDMO Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer